Loading clinical trials...
Loading clinical trials...
A Phase II Study Evaluating the Safety and Efficacy of MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment in Patients With Advanced Soft Tissue Sarcoma
Conditions
Interventions
MASCT-I
Doxorubicin
+1 more
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, China
Start Date
February 21, 2024
Primary Completion Date
February 1, 2026
Completion Date
February 1, 2027
Last Updated
July 24, 2025
NCT06422806
NCT07467772
NCT06541262
NCT06088290
NCT07432932
NCT04055220
Lead Sponsor
HRYZ Biotech Co.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions